Medical composite for preventing and curing Alzheimer's disease

Abstract

The invention discloses a medical composite for preventing and curing Alzheimer's disease (AD). The composite comprises the following raw materials in parts by weight: 10-40 parts of hyperin, 20-80 parts of icariin and 5-20 parts of Schisandrin B. Experiments of rat place navigation and space exploration prove that the medical composite of the invention can increase the ability of spatial learning and memory of AD rat model, namely reduce the escape latency and scouting distance and obviously increase the percent of scouting time in quadrant of original platform to total time and the percent of scouting distance in quadrant of original platform to total distance in space exploration experiments. Therefore, the extract composite can be used for preventing and curing AD.

Description

technical field [0001] The invention relates to a pharmaceutical composition for preventing and treating senile dementia. Background technique [0002] With the continuous acceleration of the pace of the world's entry into the aging society, various neurodegenerative senile diseases, such as mild cognitive impairment and Alzheimer's disease, have become important risk factors that threaten the health of human beings in their later years and reduce the quality of life of the elderly. The society and family have brought serious economic burden and heavy mental pressure. Therefore, the development of drugs for improving cognitive dysfunction and treating Alzheimer's disease has become the research focus of medical workers in various countries around the world, and has been highly valued by Chinese and Western medical circles. [0003] The thinking of the Western medical circles to study anti-mild cognitive impairment and senile dementia drugs based on Alzheimer's disease mainl...

AI Technical Summary

Problems solved by technology

[0003] The thinking of the Western medical circles to study anti-mild cognitive impairment and senile dementia drugs based on Alzheimer's disease mainly revolves around four anti-inflammatory (anti-inflammatory, anti-oxidation, anti-cholesterol, anti-β-amyloid protein) and two anti-( Currently, drugs approved by the US Food and Drug Administration for the treatment of Alzheimer's disease (AD) include tacrine, donepezil, rivastigmine, galantamine, and memantine. etc. Although these drugs can improve the symptoms of dementia patients in the short term, they cannot delay the development of the disease, and some of them have strong toxic and side effects on the liver, so they are hardly used at present. Some drugs are expensive and difficult for patients and their families Therefore, there is an urgent need to develop new drugs with good curative effect, few side effects and low price

Images